08:21 AM EDT, 10/15/2024 (MT Newswires) -- Ocular Therapeutix Inc ( OCUL ) said Tuesday that it has accelerated the timeline for its phase 3 clinical trial of Axpaxli to treat patients with wet age-related macular degeneration, or wet AMD.

The biopharmaceutical company said it now expects the study to be fully enrolled with all patients randomized by the end of the year, compared with its previous expectations of completing enrollment by the end of Q1 of 2025. It also said topline data from the trial are expected during Q4 of 2025.

Shares of Ocular Therapeutix ( OCUL ) were up 2.3% in recent premarket activity.

Price: 10.70, Change: +0.24, Percent Change: +2.29